Clinical trials: Reduced Physical Activity
Heart Failure
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6 minute walk test in patients with chronic HF with reduced ejection fraction (LVEF ≤ 40%) Secondary…
- Trial name
- NCT03448419
- Testing
- Empagliflozin
- Where
- 109 sites in United States, Australia and 9 more
- Volunteers
- 312 people
- Sponsor
- Boehringer Ingelheim
Insulin Resistance, Obesity
A Study of the Effect of INCB013739 on Cortisone Reducing Enzyme Activity in Obese People Predisposed to Diabetes
The purpose of this study is to determine whether the investigational drug INCB013739 has an effect on systemic and adipose tissue 11-HSD1 activity in obese, insulin resistant subjects.
- Trial name
- NCT00398619
- Testing
- INCB13739
- Where
- 2 sites in United States
- Sponsor
- Incyte Corporation
Normal and Mild Hypercholesterolemic Subjects
Long-term Effectiveness Study on Cholesterol-reducing Activity
The purpose of this study is to investigate the effect of consumption of a drinkable low fat fermented milk enriched with 0,8g or 1,6g of plant sterols on reducing plasma cholesterol (LDL-cholesterol) concentration during 12…
- Trial name
- NCT01521169
- Testing
- 1 - low-fat dairy fermented product (drinkable) enriched with plant sterols (0,8g /day equivalent as free sterols)., 2 - low-fat dairy fermented product (drinkable) enriched with plant sterols (1,6g /day equivalent as free sterols)., 3 - low-fat dairy fermented product (drinkable) without plant sterols.
- Where
- Japan
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Danone Japan
Single Ventricle Heart Disease
Evaluation of Fontan-associated Hepatic Stiffness and the Efficacy of Udenafil in Reducing Liver Stiffness
A study to evaluate the efficacy of MZ101 therapy in reducing liver stiffness.
- Trial name
- FALD (NCT03430583)
- Testing
- Udenafil
- Where
- 17 sites in United States, Canada
- Volunteers
- 88 people
- Sponsor
- Mezzion Pharma Co. Ltd
Resolution of Inflammation, Reduction of Cell Proliferation
Increased Inflammation-resolving Activity by Omega-3 Monoglycerides in Peripheral Blood Mononuclear Cells (PBMC).
The purpose of this biological study is to provide Dr. Samuel Fortin's laboratory with a continuous supply of blood mononuclear cells (PBMCs) so that he can pursue research on the potential beneficial effects of monoglyceride…
- Trial name
- PBMC (NCT05161702)
- Testing
- MAG-SPM treatment on isolated PBMC cells, Isolated PBMC cells without treatment.
- Where
- Canada
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- SCF Pharma
Metabolic Syndrome
VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt
Primary objective: To assess the effect of rimonabant on visceral fat area over a period of 12 months when prescribed with a mild hypocaloric diet in abdominally obese patients with metabolic syndrome Secondary objectives: To…
- Trial name
- VICTORIA (NCT00299325)
- Testing
- Rimonabant, Mild hypocaloric diet
- Where
- 9 sites in United States, Canada and 7 more
- Volunteers
- 254 people
- Sponsor
- Sanofi
Rheumatoid Arthritis
A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)
This open-label, single-arm study will assess the use of glucocorticoids (GC) in daily clinical practice and will evaluate the dose reduction of glucocorticoids once low disease activity is achieved in patients with rheumatoid…
- Trial name
- NCT01219933
- Testing
- methylprednisolone, tocilizumab [RoActemra/Actemra]
- Where
- 16 sites in Belgium
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
Chronic Heart Failure With Reduced Ejection Fraction
Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.
The purpose of the study was to determine the effect of LCZ696 vs. enalapril on improvement of exercise capacity in patients with chronic heart failure with reduced ejection fraction.
- Trial name
- NCT02768298
- Testing
- LCZ696, Enalapril
- Where
- 34 sites in Germany
- Volunteers
- 201 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Reduced Ejection Fraction (HFrEF)
DETERMINE-reduced - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Reduced Ejection Fraction
International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients with Reduced Ejection Fraction (HFrEF)
- Trial name
- NCT03877237
- Testing
- Dapagliflozin
- Where
- 76 sites in United States, Brazil and 7 more
- Volunteers
- 313 people
- Sponsor
- AstraZeneca
Chronic Heart Failure
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure
The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure…
- Trial name
- ATMOSPHERE (NCT00853658)
- Testing
- Enalapril, Aliskiren
- Where
- 806 sites in United States, Argentina and 42 more
- Volunteers
- 7,064 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 1
A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
This study will be conducted in participants with type 1 diabetes mellitus on continuous subcutaneous insulin infusion (CSII) or pump therapy to evaluate the effect of LY900014 (Lyumjev) on blood sugar levels during exercise…
- Trial name
- NCT05262387
- Testing
- Lyumjev with 50% basal rate reduction, Humalog with 50% basal rate reduction, Humalog with 100% basal rate reduction
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
Acute Decompensated Heart Failure, Congestive Heart Failure
Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure
This study evaluated the effect of early initiation of aliskiren therapy, compared to standard therapy, in the reduction of cardiovascular death and heart failure re-hospitalization events within 6 months, in congestive heart…
- Trial name
- ASTRONAUT (NCT00894387)
- Testing
- Aliskiren
- Where
- 308 sites in United States, Argentina and 22 more
- Volunteers
- 1,639 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Risk, Cardiovascular Disease Prevention
Digital Prevention Program With Telephonic Coaching
This study evaluates a digital health prevention program combining digital tools and structured telephonic coaching to support adult participants in improving health-related behaviors and well-being.
- Conditions
- Cardiovascular Risk, Cardiovascular Disease Prevention, Health Behavior Change, Lifestyle (Sedentary Behavior and Physical Activity)
- Trial name
- NCT07393646
- Testing
- Digital Health Platform, Telephonic Coaching
- Where
- France
- Volunteers
- 2,688 people, healthy volunteers welcome
- Sponsor
- Vivoptim Solutions
SARS-CoV-2 Infection, Lung Fibrosis
Study to Assess Efficacy and Safety of Treamid for Patients With Reduced Exercise Tolerance After COVID-19
The innovative drug Treamid is planned for use in the treatment of patients with persistent lung damage and reduced exercise tolerance exertion after COVID-19 pneumonia in a multicenter, randomized, double-blind…
- Trial name
- NCT05516550
- Testing
- Treamid, Treamid twice a day, Treamid once a day
- Volunteers
- 412 people
- Sponsor
- PHARMENTERPRISES LLC
Sleep Bruxism
Efficacy of AesyBite Active in Reducing Sleep Bruxism Activity
The overall objective of the clinical investigation is to evaluate whether the use of the AesyBite Active reduces the bruxism activity.
- Trial name
- NCT06153810
- Testing
- Biofeedback stimulation
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- Aesyra SA
Obesity
Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)
A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 6 months treatment period.
- Trial name
- RESOLVE-2 (NCT07220629)
- Testing
- NT-0796
- Where
- 9 sites in United States
- Volunteers
- 82 people
- Sponsor
- Rezera (formerly NodThera Limited)
Rheumatoid Arthritis
A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate
This 2 part study will investigate the safety, tolerability and efficacy of MabT hera in combination with RoActemra in patients with active rheumatoid arthritis despite a stable dose of methotrexate.
- Trial name
- NCT00845832
- Testing
- rituximab [MabThera/Rituxan], tocilizumab [RoActemra/Actemra]
- Where
- 24 sites in France, Germany and 6 more
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA
This study involves Rheumatoid Arthritis patients in regular clinical setting who are already on etanercept treatment and are in remission or in a low disease activity (LDA) state, and is intended to identify parameters that can…
- Trial name
- DOSERA (NCT00858780)
- Testing
- Etanercept
- Where
- 16 sites in Denmark, Finland and 4 more
- Volunteers
- 91 people
- Sponsor
- Pfizer
Non-alcoholic Fatty Liver Disease (NAFLD)
Study to Evaluate the Effectiveness of Legalon®
This is a multinational, multicentre, prospective, non-interventional study (NIS) in non-alcoholic fatty liver disease (NAFLD) patients with concomitant metabolic syndrome treated with Legalon® combined with diet and exercise.
- Trial name
- NCT05051527
- Testing
- Legalon® 140 mg
- Where
- Thailand
- Volunteers
- 362 people
- Sponsor
- Mylan Inc.
Rheumatoid Arthritis
Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis
The primary objective of this study is to assess the reduction of systemic inflammation as measured by serum levels of C-reactive protein (CRP).
- Trial name
- ACCORD-RA (NCT00545454)
- Testing
- SSR150106
- Where
- 7 sites in Bulgaria, Croatia and 5 more
- Volunteers
- 79 people
- Sponsor
- Sanofi